PDCD1 and non-small cell lung carcinoma: In the phase II ATLANTIC trial, durvalumab showed important potential in improving the efficacy for heavily pretreated (third-line or higher) patients with NSCLC when compared with other anti-PD-1/PD-L1 agents [2].